Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
35 hedge funds and large institutions have $2.74M invested in Oncternal Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 17 reducing their positions, and 12 closing their positions.
306% more call options, than puts
Call options by funds: $73K | Put options by funds: $18K
10% more capital invested
Capital invested by funds: $2.48M → $2.74M (+$258K)
19% less funds holding
Funds holding: 43 → 35 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
76% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$250K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$250K |
| 3 |
SG Americas Securities
New York
|
+$36.5K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.4K |
| 5 |
Two Sigma Advisers
New York
|
+$8.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$381K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$207K |
| 3 |
Two Sigma Investments
New York
|
-$102K |
| 4 |
State Street
Boston,
Massachusetts
|
-$77.9K |
| 5 |
VF
Virtu Financial
New York
|
-$59.8K |
ONCT Hedge Fund Activity: Q1 2019 in Review
35 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2019, worth a combined $2.74M — up 10% from $2.48M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ONCT and 4 opened new positions — a net loss of 8 holders — while 17 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $250K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $381K sold.
- 35 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2019, down from 43 in Q4 2018.
- Funds reported $2.74M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2019, up 10% quarter-over-quarter.
- 4 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2019 and 12 closed out, a net change of -8 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2019 was Renaissance Technologies, an estimated $250K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2019 was Bridgeway Capital Management, an estimated $381K sold.
Based on aggregated 13F filings for Q1 2019.